The US Food and Drug Administration is on the clock for a decision on an application for OTC naloxone before April 2023 after designating for priority review a proposal submitted by the marketer of Narcan, the Rx brand synonymous with the opioid overdose treatment.
Emergent BioSolutions, Inc.’s announcement on 6 December that the FDA had accepted its supplemental new drug application for an...







